| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Annals of Surgical Oncology, Vol 7, Issue 9 705-712, Copyright © 2000 by Society of Surgical Oncology
ARTICLES |
I. Pidhorecky, R. T. Cheney, W. G. Kraybill and J. F. Gibbs
Department of Surgical Oncology, Roswell Park Cancer Institute, State University of New York at Buffalo 14263, USA.
Gastrointestinal stromal tumors (GIST) are rare tumors of the gastrointestinal (GI) tract that arise from primitive mesenchymal cells. GISTs occur throughout the GI tract but are usually located in the stomach and small intestine. The majority of GISTs are immunohistochemically positive for c-kit protein (CD 117) and CD34. GISTs express a heterogeneous clinical course not easily predicted by standard pathological means. The most important prognostic factors are size > 5 cm, tumor necrosis, infiltration and metastasis to other sites, mitotic count > 1-5 per 10 high-powered fields, and most recently, mutation in the c-kit gene. Surgical resection remains the mainstay of treatment, as chemotherapy and radiation are ineffective. Long-term follow-up is imperative, as recurrence rates are high.
This article has been cited by other articles:
 |
|
 |
|
  B. K. P. Goh, P. K. H. Chow, W.-M. Yap, S. M. Kesavan, I.-C. Song, P. G. Paul, B.-S. Ooi, Y.-F. A. Chung, and W.-K. Wong Which Is the Optimal Risk Stratification System for Surgically Treated Localized Primary GIST? Comparison of Three Contemporary Prognostic Criteria in 171 Tumors and a Proposal for a Modified Armed Forces Institute of Pathology Risk Criteria Ann. Surg. Oncol., August 1, 2008; 15(8): 2153 - 2163. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T Armbrust, M Sobotta, and G Ramadori Follow up of three cases after adjuvant treatment of high risk gastrointestinal stromal tumors with Imatinib Ann. Onc., June 1, 2007; 18(6): 1123 - 1125. [Full Text] [PDF]
|
|
|
|
 |
|
 C. P. Raut, M. Posner, J. Desai, J. A. Morgan, S. George, D. Zahrieh, C. D.M. Fletcher, G. D. Demetri, and M. M. Bertagnolli Surgical Management of Advanced Gastrointestinal Stromal Tumors After Treatment With Targeted Systemic Therapy Using Kinase Inhibitors J. Clin. Oncol., May 20, 2006; 24(15): 2325 - 2331. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Salazar, A Barata, S Andre, J Venancio, I Francisco, M Cravo, and C Nobre-Leitao First report of a complete pathological response of a pelvic GIST treated with imatinib as neoadjuvant therapy. Gut, April 1, 2006; 55(4): 585 - 586. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Sandrasegaran, A. Rajesh, J. Rydberg, D. A. Rushing, F. M. Akisik, and J. D. Henley Gastrointestinal Stromal Tumors: Clinical, Radiologic, and Pathologic Features Am. J. Roentgenol., March 1, 2005; 184(3): 803 - 811. [Full Text] [PDF]
|
|
|
|
|
|
B. L. Eisenberg and I. Judson Surgery and Imatinib in the Management of GIST: Emerging Approaches to Adjuvant and Neoadjuvant Therapy Ann. Surg. Oncol., May 1, 2004; 11(5): 465 - 475. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Gayed, T. Vu, R. Iyer, M. Johnson, H. Macapinlac, N. Swanston, and D. Podoloff The Role of 18F-FDG PET in Staging and Early Prediction of Response to Therapy of Recurrent Gastrointestinal Stromal Tumors J. Nucl. Med., January 1, 2004; 45(1): 17 - 21. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Goyal, R E Mansel, and S Goyal Gastrointestinal stromal tumour in an inguinal hernial sac: an unusual presentation Postgrad. Med. J., December 1, 2003; 79(938): 707 - 708. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Sakamoto, J. Yamamoto, H. Takahashi, N. Kokudo, T. Yamaguchi, T. Muto, and M. Makuuchi Segmental Resection of the Third Portion of the Duodenum for a Gastrointestinal Stromal Tumor: a Case Report Jpn. J. Clin. Oncol., July 1, 2003; 33(7): 364 - 366. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hole and D. Blake A review of imatinib mesilate in the treatment of patients with gastrointestinal stromal tumours and chronic myeloid leukaemia Journal of Oncology Pharmacy Practice, March 1, 2003; 9(1): 1 - 14. [Abstract] [PDF]
|
|
|
|
 |
|
 G. J. C. Burkill, M. Badran, O. Al-Muderis, J. Meirion Thomas, I. R. Judson, C. Fisher, and E. C. Moskovic Malignant Gastrointestinal Stromal Tumor: Distribution, Imaging Features, and Pattern of Metastatic Spread Radiology, February 1, 2003; 226(2): 527 - 532. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. T. Consorti, T. H. Liu, and A. McGee Image of the Month Arch Surg, November 1, 2002; 137(11): 1311 - 1312. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Dagher, M. Cohen, G. Williams, M. Rothmann, J. Gobburu, G. Robbie, A. Rahman, G. Chen, A. Staten, D. Griebel, et al. Approval Summary: Imatinib Mesylate in the Treatment of Metastatic and/or Unresectable Malignant Gastrointestinal Stromal Tumors Clin. Cancer Res., October 1, 2002; 8(10): 3034 - 3038. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Cohen, R. Dagher, D. J. Griebel, A. Ibrahim, A. Martin, N. S. Scher, G. H. Sokol, G. A. Williams, and R. Pazdur U.S. Food and Drug Administration Drug Approval Summaries: Imatinib Mesylate, Mesna Tablets, and Zoledronic Acid Oncologist, October 1, 2002; 7(5): 393 - 400. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Fletcher, C. D.M. Fletcher, B. P. Rubin, L. K. Ashman, C. L. Corless, M. C. Heinrich, J. Andersson, H. Sjogren, J. Meis-Kindblom, G. Stenman, et al. KIT Gene Mutations in Gastrointestinal Stromal Tumors : More Complex than Previously Recognized? Am. J. Pathol., August 1, 2002; 161(2): 737 - 739. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
